Why Was the Azithromycin "for Life" Trial Necessary?

Maitland K., Walker AS.

DOI

10.1056/NEJMe2407000

Type

Other

Publication Date

22/08/2024

Volume

391

Pages

760 - 762

Keywords

Humans, Anti-Bacterial Agents, Azithromycin, Randomized Controlled Trials as Topic, Infant, Child, Preschool, Niger, Infant Mortality, Child Mortality, Mass Drug Administration, Chemoprevention, Drug Resistance, Bacterial, Bacterial Infections

Permalink Original publication